A possible involvement of solvent-induced interactions in drug design

Journal of Medicinal Chemistry

Volumn 39, Issue 7, 1996, Pages 1531-1539

  Wang, Hongwu ^a,b   Ben Naim, Arieh ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HEPTYLPHOSPHONYL 1 OCTYLGLYCERO 3 PHOSPHOETHANOLAMINE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; A 78791; CONGOCIDINE; HOECHST 32528; PHOSPHOLIPASE A2; PHOSPHOLIPASE INHIBITOR; PROTEINASE INHIBITOR; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DNA INTERACTION; DRUG SOLUBILITY; HYDROPHOBICITY; PROTEIN DOMAIN;

AMINO ACID CHLOROMETHYL KETONES; ANTITHROMBINS; BASE SEQUENCE; BINDING SITES; DNA; DRUG DESIGN; ENZYME INHIBITORS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HYDROGEN BONDING; INDENES; MOLECULAR SEQUENCE DATA; NETROPSIN; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOLIPASES A; PROTEIN BINDING; PROTEIN FOLDING; SOLVENTS; THERMODYNAMICS; THROMBIN;

EID: 0029989480     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950430d     Document Type: Article

References (25)

1. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078.
2. Perun, T. J.; Propst, C. L. Computer-Aided Drug Design; Marcel Dekker, Inc.: New York, 1989.
3. Propst, C. L.; Perun, T. J. Nucleic Acid Targeted Drug Design; Marcel Dekker, Inc.: New York, 1992.
4. Greer, J.; Erickson, J. W.; Baldwin, J. J.; Varney, M. D. Application of the three dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. 1994, 37, 1035.
5. Roerdink, F. H.; Kroon, A. M. Drug Carrier Systems; John Wiley and Sons: New York, 1989.
6. Ben-Naim, A. Solvent induced interactions, Hydrophobic hydrophilic phenomena. J. Chem. Phys. 1989, 90, 7412.
7. Ben-Naim, A. Solvent effect on protein association and protein folding. Biopolymer 1990, 29, 567.
8. Ben-Naim, A.; Ting, K. L.; Jernigan, R. L. Solvation thermodynamics of biopolymers. Biopolymers 1990, 28, 1309.
9. Ben-Naim, A.; Ting, K. L.; Jernigan, R. L. Solvent effects on binding thermodynamics of biopolymers. Biopolymer 1990, 29, 901.
10. Ben-Naim, A. Statistical Thermodynamics for Chemists and Biochemists; Plenum Press: New York, 1992.
11. Ben-Nairn, A. Strong forces between hydrophobic macromolecules. J. Chem. Phys. 1991, 93, 8196.
12. Ben-Naim, A. Solvation Thermodynamics; Plenum Press: New York, 1987.
13. PL does not include the direct interaction energy between P and L.
14. Wilf, J.; Ben-Naim, A. Direct measurement of intramolecular hydrophobic interactions. J. Phys. Chem. 1994, 98, 8594.
15. Hosur, M. V.; Bhat, T. N.; Kempf, D.; Baldwin, E. T.; Liu, B.; Gulnik, S.; Wideburg, N. E.; Norbeck, D. W.; Appelt, K.; Erickson, J. W. Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1994, 116, 847.
16. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F.; Brice, M. D., Rodger, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The protein data bank, a computer-based archival file for macromolecular structures. Eur. J. Biochem. 1977, 80, 319.
17. Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schlief, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I. W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443.
18. Kempf, D. J.; Marsh, K. C.; Fino, L. C.; Bryant, P.; Kennard, A. C.; Sham, H. L.; Zhao, C.; Vasavanonda, S.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Green, B. E.; Herrin, T.; Norbeck, D. W. Design of orally bioavailable symmetry-based inhibitors of HIV protease. Bioorg. Med. Chem. 1994, 2, 847.
19. Tapparelli, C.; Metternich, R.; Ehrhardt, C.; Cook, N. S. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharm. Sci. 1993, 14, 366.
20. Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. The refined 1.9 angstroms crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg Chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8, 3467.
21. Scott, D. L.; White, S. P.; Browning, J. L.; Rosa, J. J.; Gelb, M. H.; Sigler, P. B. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science 1991, 254, 1007.
22. Krugh, T. R. Drug-DNA interactions. Curr. Opin. Struct. Biol. 1994, 4, 868.
23. Tabernero, L.; Verdaguer, N.; Coll, M.; Fita, I.; Marel, G. A.; Boom, J. H.; Rich, A.; Aymami, J. Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor groove binding drug Netropsin. Biochemistry 1993, 32, 8403.
24. Sriram, M.; Marel, G. A.; Roelen, H.; Boom, J. H.; Wang, A. J. Conformation of B-DNA containing O6-ethyl-G-C base pairs Stabilized by minor groove binding drugs: Molecular structure of d(CGC[E6G]AATTCGCG) complexed with Hoechst 33258 or Hoechst 33342. EMBO J. 1992, 11, 225.
25. Mezei, M.; Ben-Naim, A. Calculation of the solvent contribution of the potential of mean force between two water molecules. J. Chem. Phys. 1990, 92, 1359.